Recent Papers on Rhabdomyosarcoma – 12 January 2014

Please note that some are abstracts requiring subscriptions or purchase of the full article, others provide a more comprehensive view of the paper. An approach to pleomorphic sarcomas: can we subclassify, and does it matter&quest JR Goldblum - Modern Pathology, 2014 ... Pleomorphic rhabdomyosarcoma is recognized by the presence of large cells with eosinophilic cytoplasm…
Continue Reading »

What Promising Drugs are on the Horizon?

20131225- Cynthia asked a valid question in response to a prior blog post: what new treatments look most promising for relapsed metastatic alveolar rhabdomyosarcoma? The most relevant answer is that the human relapsed rhabdomyosarcoma study ARST-0921 (bevacizumab vs temsirolimus) may have early results worth discussing with one's physician. The second most relevant answer is that…
Continue Reading »

We Want to Answer Your Questions About Rhabdo…

This is Charles (researcher). Lenny Wexler and I are in the midst of creating the scientific advisory board that complements the wider scientific advisory council. that said, we are happy to post short blogs about the topics of interest to you (with select links to more in-depth references). Quick ground rules: general topics are welcome,…
Continue Reading »

FDA Public Workshops on Rare Childhood Diseases

Jennifer Inman-Cartwright emailed me today saying that she sat in on a conference call with the Children's Cancer Caucus - Advocacy (CCCA) where the topic was the FDA and orphan drug issues. She forward the slide presentations which you can view and download. The first presentation was by James E. Valentine, MHS, JD Candidate at…
Continue Reading »

Early Life Factors and Risk of Childhood Rhabdomyosarcoma

By: Anshu Shrestha, Beate Ritz, Simona Ognjanovic, Christina A. Lombardi, Michelle Wilhelm and Julia E. Heck Frontiers in Public Health, 31 May 2013 - Although little is known about etiology of childhood rhabdomyosarcoma (RMS), early life factors are suspected in the etiology. We explored this hypothesis using linked data from the California Cancer Registry and…
Continue Reading »

CytRx Reports Highly Statistically Significant Positive Results from its Global Phase 2b Clinical Trial

CytRx, a biopharmaceutical research and development company specializing in oncology, today announced highly positive top-line efficacy results from a multicenter, randomized, open-label global Phase 2b clinical trial. The trial investigated the efficacy and safety of aldoxorubicin compared with doxorubicin in subjects with first-line metastatic, locally advanced or unresectable soft tissue sarcomas (STS). Aldoxorubicin combines the…
Continue Reading »

Gene Sequencing Project Finds Family of Drugs with Promise for Treating Childhood Tumor

(MEMPHIS, Tenn. – December 9, 2013) Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children's Research Hospital–Washington University…
Continue Reading »
Skip to toolbar